2024
Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis
Park D, Hu J, Campbell G, Goldwag K, Kelsey M, Altin S, Gallegos-Kattán C, Nanna M. Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis. Journal Of The Society For Cardiovascular Angiography & Interventions 2024, 3: 101859. PMID: 39131993, PMCID: PMC11307649, DOI: 10.1016/j.jscai.2024.101859.Peer-Reviewed Original ResearchMonths of DAPTDuration of dual antiplatelet therapyNet adverse clinical eventsType 2 diabetes mellitusDual antiplatelet therapyAcute coronary syndromeRandomized controlled trialsSensitivity analysis of trialsPercutaneous coronary interventionCoronary interventionNo significant differenceAntiplatelet therapyAnalysis of trialsCoronary syndromeControlled trialsMeta-analysis of patientsStent thrombosisMeta-analysisDAPT durationClinicians greater flexibilityStudy-level meta-analysisOptimal duration of dual antiplatelet therapyHigher risk of adverse eventsPostpercutaneous coronary interventionRisk of adverse eventsShorter Dual Antiplatelet Therapy for Older Adults After Percutaneous Coronary Intervention
Park D, Hu J, Jamil Y, Kelsey M, Jones W, Frampton J, Kochar A, Aronow W, Damluji A, Nanna M. Shorter Dual Antiplatelet Therapy for Older Adults After Percutaneous Coronary Intervention. JAMA Network Open 2024, 7: e244000. PMID: 38546647, PMCID: PMC10979312, DOI: 10.1001/jamanetworkopen.2024.4000.Peer-Reviewed Original ResearchConceptsOlder adultsMonths of DAPTDuration of dual antiplatelet therapySystematic reviewRandomized clinical trialsPercutaneous coronary interventionMeta-analysisPreferred Reporting ItemsAssess data qualityRisk of bleedingDuration of DAPTDual antiplatelet therapyWeb of ScienceMain OutcomesReporting ItemsData extractionAbstracted dataSecondary outcomesRisk ratioAntiplatelet therapyPrimary outcomeCochrane LibraryCoronary interventionReference groupNetwork meta-analysis
2022
Shortening the duration of dual antiplatelet therapy after percutaneous coronary intervention for acute coronary syndrome: A systematic review and meta-analysis
Park DY, Wang P, An S, Grimshaw AA, Frampton J, Ohman EM, Rao SV, Nanna MG. Shortening the duration of dual antiplatelet therapy after percutaneous coronary intervention for acute coronary syndrome: A systematic review and meta-analysis. American Heart Journal 2022, 251: 101-114. PMID: 35654162, PMCID: PMC10904033, DOI: 10.1016/j.ahj.2022.05.019.Peer-Reviewed Original ResearchConceptsMonths of DAPTHazard ratioIschemic eventsDuration of DAPTSelect patient characteristicsDual antiplatelet therapyAcute coronary syndromeCoronary artery lesionsPercutaneous coronary interventionConfidence intervalsAssociation of outcomesRandom-effects modelComprehensive literature searchMeta-regression analysisMajor bleedingAntiplatelet therapyCoronary syndromeArtery lesionsCoronary interventionControlled TrialsPatient characteristicsPrespecified outcomesGreater proportionSimilar efficacySystematic review
2021
Bridging Antiplatelet Therapy After Percutaneous Coronary Intervention JACC Review Topic of the Week
Sullivan AE, Nanna MG, Wang TY, Bhatt DL, Angiolillo DJ, Mehran R, Banerjee S, Cantrell S, Jones WS, Rymer JA, Washam JB, Rao SV, Ohman EM. Bridging Antiplatelet Therapy After Percutaneous Coronary Intervention JACC Review Topic of the Week. Journal Of The American College Of Cardiology 2021, 78: 1550-1563. PMID: 34620413, DOI: 10.1016/j.jacc.2021.08.013.Peer-Reviewed Original ResearchConceptsDual antiplatelet therapyAntiplatelet therapyBridging therapySmall-molecule glycoprotein IIb/IIIa inhibitorsGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsIntravenous antiplatelet agentsOptimal antiplatelet strategyPerioperative risk factorsCoronary stent implantationMultidisciplinary risk assessmentIntravenous P2YEarly surgeryHemorrhagic complicationsAntiplatelet strategiesClinical characteristicsAntiplatelet agentsPerioperative careRisk stratificationComplex patientsStent implantationRisk factorsCurrent guidelinesOptimal managementTherapy
2019
A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention
Sullivan AE, Nanna MG, Rao SV, Cantrell S, Gibson CM, Verheugt FWA, Peterson ED, Lopes RD, Alexander JH, Granger CB, Yee MK, Kong DF. A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Catheterization And Cardiovascular Interventions 2019, 96: e102-e109. PMID: 31713326, PMCID: PMC7211549, DOI: 10.1002/ccd.28535.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAnticoagulantsAtrial FibrillationCoronary ThrombosisDual Anti-Platelet TherapyFemaleFibrinolytic AgentsHemorrhageHumansMalePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsRandomized Controlled Trials as TopicRisk FactorsTreatment OutcomeConceptsPercutaneous coronary interventionAcute coronary syndromeDouble therapyOral anticoagulationAtrial fibrillationTriple therapyAntithrombotic therapyCoronary syndromeCoronary interventionStent thrombosisMajor adverse cardiovascular eventsTriple antithrombotic therapyAdverse cardiovascular eventsDual antiplatelet therapyOptimal antithrombotic therapyGood safety profileRandom-effects modelIschemic outcomesAntiplatelet therapyCardiovascular eventsP2Y12 inhibitorsMedical managementRandomized trialsIntracranial hemorrhageSafety profile